• Login
    View Item 
    •   Athenaeum Home
    • BioMed Central Open Access Articles
    • Open Access Articles by UGA Faculty
    • View Item
    •   Athenaeum Home
    • BioMed Central Open Access Articles
    • Open Access Articles by UGA Faculty
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Tuberous sclerosis complex neuropathology requires glutamate-cysteine ligase

    Thumbnail
    View/Open
    40478_2015_Article_225.pdf (1.936Mb)
    Date
    2015-07-30
    Author
    Malik, Anna R
    Liszewska, Ewa
    Skalecka, Agnieszka
    Urbanska, Malgorzata
    Iyer, Anand M
    Swiech, Lukasz J
    Perycz, Malgorzata
    Parobczak, Kamil
    Pietruszka, Patrycja
    Zarebska, Malgorzata M
    Macias, Matylda
    Kotulska, Katarzyna
    Borkowska, Julita
    Grajkowska, Wieslawa
    Tyburczy, Magdalena E
    Jozwiak, Sergiusz
    Kwiatkowski, David J
    Aronica, Eleonora
    Jaworski, Jacek
    Metadata
    Show full item record
    Abstract
    Abstract Introduction Tuberous sclerosis complex (TSC) is a genetic disease resulting from mutation in TSC1 or TSC2 and subsequent hyperactivation of mammalian Target of Rapamycin (mTOR). Common TSC features include brain lesions, such as cortical tubers and subependymal giant cell astrocytomas (SEGAs). However, the current treatment with mTOR inhibitors has critical limitations. We aimed to identify new targets for TSC pharmacotherapy. Results The results of our shRNA screen point to glutamate-cysteine ligase catalytic subunit (GCLC), a key enzyme in glutathione synthesis, as a contributor to TSC-related phenotype. GCLC inhibition increased cellular stress and reduced mTOR hyperactivity in TSC2-depleted neurons and SEGA-derived cells. Moreover, patients’ brain tubers showed elevated GCLC and stress markers expression. Finally, GCLC inhibition led to growth arrest and death of SEGA-derived cells. Conclusions We describe GCLC as a part of redox adaptation in TSC, needed for overgrowth and survival of mutant cells, and provide a potential novel target for SEGA treatment.
    URI
    http://dx.doi.org/10.1186/s40478-015-0225-z
    http://hdl.handle.net/10724/31953
    Collections
    • Open Access Articles by UGA Faculty

    About Athenaeum | Contact Us | Send Feedback
     

     

    Browse

    All of AthenaeumCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    About Athenaeum | Contact Us | Send Feedback